Recombinant modified-C reactive protein: Immtech reported that Phase I testing in 20 HIV-infected men showed safety and a favorable response on immune, hematopo

The recombinant agent inhibited HIV infection in donor white blood cell lines, as measured by p24 antigen assay, and worked even when added to cultures after 72 hours of infection. Testing against SIV in monkeys also has been carried out, the company reported, with potentiation of immune and platelet activities, and possible antiviral effects. ...